<DOC>
	<DOC>NCT01887067</DOC>
	<brief_summary>To demonstrate the efficacy of renal denervation therapy in treating resistant hypertension and its effect on glucose metabolism in patients with type 2 diabetes mellitus</brief_summary>
	<brief_title>Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Age ranges from 18 to 70 years inclusive Essential hypertension Office Systolic BP (SBP) ≥ 150 mmHg or Diastolic BP (DBP) ≥ 90mmHg 3 or more antihypertensive medications of different classes, including a diuretic, or documented intolerance to multiple medications Type 2 Diabetes Mellitus on oral hypoglycaemic agent (OHA) 2 functional kidneys; eGFR ≥ 45 mL/min/1.73m² (MDRD formula) Suitable renal anatomy compatible with the endovascular denervation procedure Individual has renal artery anatomy that is ineligible for treatment including: Patients with secondary hypertension Myocardial infarction, unstable angina pectoris, cerebrovascular accident within 6 months Patient with type 1 diabetes mellitus Patient on insulin due to oral drug failure Renovascular abnormalities (including severe renal artery stenosis, previous renal stenting or angioplasty, or known dual renal arteries) Pregnancy Patient with any implantable device incompatible with radiofrequency energy delivery Hemodynamically significant valvular heart disease for which reduction of BP would be considered hazardous Any serious medical condition, which in the opinion of the investigator, may limit the life expectancy of patients or adversely</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Diabetes Mellitus</keyword>
</DOC>